Nicole Lamanna, MD, discusses the significance of the 3-year follow-up data from the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia.
Nicole Lamanna, MD, associate professor and CLL director at the Columbia University Irving Medical Center, discusses the significance of the 3-year follow-up data for the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Patients had a progression-free survival (PFS) rate of 71% with a fixed duration of venetoclax (Venclexta) plus rituximab (Rituxan), compared to about 17% with bendamustine plus rituximab.
All patients had stopped venetoclax treatment at 2 years; these data were also broken down based on minimal residual disease (MRD) for further follow-up. In this analysis, Lamanna says there was a significant correlation between those who had undetectable disease and those who did very well.
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More